UroAlert - GU Oncology Weekly

May 21, 2026

Videos

Peer-to-Peer Clinical Conversations

ECOG-ACRIN 8192 Evaluates Preoperative Gemcitabine Plus Durvalumab in Cisplatin-Ineligible UTUC - Jeannie Hoffman-Censits

Jean Hoffman-Censits

Jeannie Hoffman-Censits discusses ECOG-ACRIN 8192 Arm C, a prospective study of four cycles of preoperative gemcitabine plus durvalumab before radical nephroureterectomy in cisplatin-ineligible patients with high-grade upper tract urothelial cancer.

Shifting from Surgery to Chemoablation for Low-Grade Bladder Cancer Treatment - Katie Murray

Katie Murray

Zachary Klaassen is joined by Katie Murray to discuss chemoablation with mitomycin (ZUSDURI™) for low-grade intermediate-risk non-muscle invasive bladder cancer.

Beyond the Abstracts

Exploring the Influence of the Bladder Microbiome on BCG Immunotherapy Outcomes for High-Risk Non Muscle Invasive Bladder Cancer - Beyond the Abstract

Nivolumab in Metastatic Clear-cell Renal Cell Carcinoma: An Integrative Biomarker Analysis from the NIVOREN GETUG-AFU 26 Phase 2 Study - Beyond the Abstract

Conference Coverage

AUA 2026: Comparison between IO–IO and IO–TKI Combination Therapies for Renal Cell Carcinoma with Inferior Vena Cava Tumor Thrombus

AUA 2026: Perspectives of Running Clinical Trials as a Urologist in Community Practice

AUA 2026: Long-Term Follow-Up Results of aMVAC Arm of ECOG-ACRIN EA8141: a Prospective Phase II Trial of Neoadjuvant Systemic Chemotherapy Followed by Extirpative Surgery for Patients with High-Grade Upper Tract Urothelial Carcinoma

AUA 2026: Interim Analysis of Light-Activated TLD-1433 in a Phase II Clinical Study of BCG-Unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma In-Situ

AUA 2026: Association of a Computational Histology AI (CHAI) Prognostic Biomarker with High Grade Recurrence Independent of Traditional Risk Factors in Low Grade Non-Muscle Invasive Bladder Cancer

Articles

Editor Selected Abstracts and Commentaries

Bladder Cancer

ImmunityBio Announces FDA Acceptance of Supplemental BLA for ANKTIVA® Plus BCG in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer with Papillary Disease; PDUFA Date Set for January 6, 2027

Role of Bladder EpiCheck® in Bladder cancer: from primary diagnosis to surveillance.

Beyond the Tumor: Exploring the Financial Toxicity of Non-Muscle Invasive Bladder Cancer in a Diverse, Urban Population.

TROPION-Urothelial03: a phase II/III study of datopotamab deruxtecan (Dato-DXd) for locally advanced or metastatic urothelial carcinoma.

Perioperative Treatment Patterns for Muscle-Invasive Bladder Cancer Patients Undergoing Radical Cystectomy in the Adjuvant Immunotherapy Era: A Retrospective Analysis of US Community Oncology Practice.

Survivor-identified barriers and facilitators to acute phase recovery following radical cystectomy.

Cost-Effectiveness of Immune Checkpoint Inhibitor Therapy plus BCG for High-Risk Non-muscle Invasive Bladder Cancer: Analyses of CREST, POTOMAC, and ALBAN.

Real-World Utility of Cxbladder Triage for Patients with Microhematuria: A Matched Cohort Study.

Years of Life Lost in Patients with Muscle-Invasive and Metastatic Bladder Cancer.

Non-muscle-invasive urothelial carcinoma of the bladder: time for a de-escalation of treatment and aftercare.

Time toxicity of intravesical BCG versus sequential intravesical gemcitabine and docetaxel for non-muscle-invasive bladder cancer.

Under-reporting of carcinoma in situ in patients with high-grade papillary non-muscle-invasive bladder cancer.

Perioperative Systemic Treatment Options for Muscle-Invasive Bladder Cancer.

FDA Approves Genentech’s Tecentriq for Adjuvant Muscle-Invasive Bladder Cancer with ctDNA-Guided Treatment

A Spatial Atlas of Muscle-Invasive Bladder Cancer Reveals Lineage-Specific Vulnerabilities and Immune Architecture.

Perioperative IMFINZI® (Durvalumab) plus Neoadjuvant EV Showed Statistically Significant and Clinically Meaningful Improvements in Event-Free Survival and Overall Survival in Muscle-Invasive Bladder Cancer in the Phase III VOLGA Trial

Multi-institutional external validation of the European risk classification for high-grade Ta non-muscle-invasive bladder cancer.

Outcomes of Intermediate Risk Non-muscle-invasive Bladder Cancer Receiving Adjuvant Treatment: A Pooled Analysis of Four Randomized Controlled Trials.

Population-Based Outcomes of Chemoradiation Therapy for Muscle-Invasive Bladder Cancer in Older Adults - Beyond the Abstract

Advances and Challenges of PET Imaging in Bladder Cancer-an Update and Future Trends - Beyond the Abstract

Real-World Effectiveness of Avelumab, Pembrolizumab, and Enfortumab Vedotin in Patients with Advanced Urothelial Carcinoma with Squamous Differentiation (ARON-2EV) - Beyond the Abstract

Renal Cancer

Survival outcomes after cytoreductive nephrectomy with tumor thrombectomy: results from the Intercontinental Collaboration on Renal Cell Carcinoma.

Refining Prognosis in Advanced Renal Cell Carcinoma: International Real-World Validation of the Meet-URO Score in First-Line Immunotherapy Combinations.

Evaluation of algorithms for predicting new baseline renal function after complex partial nephrectomy for multifocal renal tumors.

Complete response in metastatic clear cell renal cell carcinoma following pembrolizumab-axitinib and subsequent nephrectomy: a Case Report.

Dissecting the Tumor Microenvironment to Identify Biomarkers of Outcome to Anti-PD-1 Therapy in Clear Cell Renal Cell Carcinoma: analyses of the HCRN GU16-260 trial.

Long-term outcomes of stereotactic ablative body radiotherapy for primary kidney cancer (TROG 15.03 FASTRACK II): a multicentre, non-randomised, phase 2 study.

Sutureless Purely Off-clamp Robotic Partial Nephrectomy: Evidence from a Randomized Controlled Noninferiority Trial.

Comparative and Critical Analysis of Immune-based Combinations for First-line Treatment of Metastatic Renal Cell Carcinoma.

C-Reactive Protein/Albumin Ratio (CAR)-Integrated IMDC Model Improves Risk Stratification in Metastatic Renal Cell Carcinoma.

Nephron Sparing Treatment (NEST) for small renal masses: understanding patients' and clinicians' experiences of a cohort-embedded randomised control trial.

Development of the PREDICT-Kidney Online Tool to Promote Informed Decision-Making About Kidney Cancer Follow-up Care: A Qualitative Co-Design Study - Beyond the Abstract

Prostate Cancer

Radiochemistry and comparative in vitro assessment of PSMA-617 labeled with lead-212 (212Pb), actinium-225 (225Ac), and lutetium-177 (177Lu).

Failure of a LHRH agonist in metastatic prostate cancer: a case report and review of literature.

Active surveillance for intermediate risk prostate cancer: the Manitoba Prostate Center experience.

The predictive role of [177Lu]Lu-PSMA-617 SPECT/CT semiquantitative parameters from the 1st RLT cycle in advanced mCRPC: a preliminary bicentric lesion-based analysis.

GMP-compliant automated synthesis and quality control of [177Lu]Lu-PSMA-I&T using the GAIA/LUNA Elysia-Raytest module for the treatment of metastatic castration-resistant prostate cancer.

Marital status and post-radical prostatectomy outcomes: results from the SEARCH database.

From 18F-choline to prostate-specific membrane antigen PET: lessons from early multiparametric kinetic modelling in prostate cancer.

The evolving PI-RADS paradigm.

The Diagnostic Role of Prostate-specific Membrane Antigen Positron Emission Tomography for Patients with Rising PSA After Radical Prostatectomy and Postoperative Radiotherapy: A Systematic Review and Meta-analysis.

Intra-fraction target motion during MR-guided prostate stereotactic body radiotherapy: the importance of adaptive planning and real-time motion management.

Co-Targeting Nuclear Export and Translation Initiation Uncovers a Therapeutic Vulnerability in Lethal Prostate Cancer.

Dependencies in heterogeneous, lineage plastic patient-derived prostate cancer organoids revealed through integrated single-cell multiomics and CRISPR screening.

Germline polygenic score for prostate cancer aggressiveness.

Community voices, strategies to improve understanding, and access to prostate cancer genomic testing.

Early outcomes of partial gland (focal) salvage brachytherapy for radiorecurrent prostate cancer.

Intrafraction Motion Mitigation by Rectal Spacers in Prostate SBRT: Balloon, Hydrogel, and No-Spacer Comparison.

Prognostic Impact of TP53 and RB1 Alterations in Metastatic Castration-Resistant Prostate Cancer Treated with Docetaxel.

IL-12-engineered human PSMA-CAR T cells for the treatment of advanced prostate cancer.

Pelvic nodes ultra-hypo fractionated versus conventionally fractionated IMRT with HDR brachytherapy in prostate cancer: interim analysis of a collaborative multi-institutional non-inferiority phase 3 trial (PCS-XI, NCT05820633).

NCCN Guidelines® Insights: Prostate Cancer, Version 5.2026.

Identification of CAND1 as a DNA-dependent protein kinase-regulated coactivator of androgen receptor and the ARv7 splice variant.

Response assessment in [177Lu]PSMA: where do we stand?

Anthropometric assessment of obesity in robotic-assisted laparoscopic prostatectomy: A systematic review.

Contrast-free MRI-first screening in young asymptomatic men: Prostate characteristics and cancer detection rates.

Semen RNA-Based Biomarkers for Prostate Cancer Detection and Risk Stratification: A Prospective Multi-Center Validation Study.

NeuroSAFE-guided robot-assisted radical prostatectomy versus standard RARP: systematic review and meta-analysis of comparative studies.

Phase II Trial of Combination Radiation, Hormone, and Immunotherapy in Grade Group 5 Prostate Cancer - Beyond the Abstract

Therapeutic Targeting of Prostate-Specific Membrane Antigen Could Limit Its Potential as Benchmark Imaging - Beyond the Abstract

Upper Tract Tumors

Adverse impact of bladder biopsy on the rate of intravesical recurrences following radical nephroureterectomy for upper tract urothelial carcinoma.

Patterns of adjuvant intracavitary instillation and recurrence after endoscopic management of upper tract urothelial carcinoma.

Rapid Systemic Progression After Ureteroscopic Holmium:YAG Laser Ablation for High-Grade Upper Tract Urothelial Carcinoma in a Solitary Kidney: A Case Report.

Diagnostic Accuracy of Liquid-Based Biomarkers for Detecting and Risk Stratifying Upper Tract Urothelial Cancers: A Diagnostic Test Systematic Review by the EAU Guidelines UTUC Panel.

Testicular Cancer

Residence Near Agricultural Crops at Birth and Risk of Adult Testicular Germ Cell Tumors: A French Nationwide Case-Control Study Using Historical Aerial GIS Data.

Robotic retroperitoneal lymph node dissection: a stepwise technical guide.

How to Optimize Treatment for Patients With Poor-Risk Testicular Cancer.

TNFSF10: a promising prognostic biomarker and therapeutic target for immunotherapy in testicular germ cell tumors.

CONNECT WITH US

Questions or Comments? Email us at editors@urotoday.com

Digital Science Press, LLC
2011 Phaethon Lane,
Reno, NV 89523

You are receiving this email because you have chosen to receive emails from UroToday.

Add us to your address book View this email as a web page Forward to a colleague Manage your subscriptions Unsubscribe

Copyright ©2026 Digital Science Press, LLC